Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
240 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sepsis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Sepsis - Pipeline Review, H2 2016', provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects - The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Sepsis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sepsis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Sepsis Overview 11 Therapeutics Development 12 Pipeline Products for Sepsis - Overview 12 Pipeline Products for Sepsis - Comparative Analysis 13 Sepsis - Therapeutics under Development by Companies 14 Sepsis - Therapeutics under Investigation by Universities/Institutes 19 Sepsis - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Sepsis - Products under Development by Companies 25 Sepsis - Products under Investigation by Universities/Institutes 30 Sepsis - Companies Involved in Therapeutics Development 31 Adrenomed AG 31 Altor BioScience Corporation 32 Am-Pharma B.V. 33 Arch Biopartners, Inc. 34 Aridis Pharmaceuticals LLC 35 Asahi Kasei Pharma Corp. 36 Astellas Pharma Inc. 37 Batu Biologics, Inc. 38 Biomedica Management Corporation 39 Boehringer Ingelheim GmbH 40 Bristol-Myers Squibb Company 41 Cell2B S.A. 42 Chiesi Farmaceutici SpA 43 Chiome Bioscience, Inc. 44 Cilian AG 45 Cognosci, Inc. 46 Cytheris SA 47 Endacea, Inc. 48 Evec, Inc. 49 Huons Co., Ltd. 50 Immune Response BioPharma, Inc. 51 Immunethep, SA 52 ImmunNovative Developments SL 53 InflaRx GmbH 54 Inotrem S.A. 55 Integrated BioTherapeutics, Inc. 56 Lead Discovery Center GmbH 57 Merck & Co., Inc. 58 Navigen Pharmaceuticals, Inc. 59 OncoImmune, Inc. 60 Opsona Therapeutics Limited 61 Orion Oyj 62 ProThera Biologics, LLC. 63 Ra Pharmaceuticals, Inc. 64 Recce Pty Ltd 65 Ribomic Inc. 66 Shionogi & Co., Ltd. 67 Silence Therapeutics Plc 68 SK Biopharmaceuticals Co., Ltd. 69 Stemedica Cell Technologies, Inc. 70 Syntiron LLC 71 TaiRx, Inc. 72 Takeda Pharmaceutical Company Limited 73 Therakind Limited 74 Therashock, LLC 75 TiGenix NV 76 VBS Pharmaceuticals 77 ViiV Healthcare Limited 78 XImmune AB 79 Sepsis - Therapeutics Assessment 80 Assessment by Monotherapy Products 80 Assessment by Target 81 Assessment by Mechanism of Action 84 Assessment by Route of Administration 87 Assessment by Molecule Type 89 Drug Profiles 91 3K3A-APC - Drug Profile 91 7-H9 - Drug Profile 93 AB-022 - Drug Profile 94 AcPepA - Drug Profile 95 adrecizumab - Drug Profile 96 ALT-836 - Drug Profile 97 AM/AMBP-1 - Drug Profile 99 Aspidasept - Drug Profile 100 Atu-111 - Drug Profile 101 BI-113823 - Drug Profile 102 Biologic to Inhibit PD-L1 for Immunology - Drug Profile 103 BMS-936559 - Drug Profile 104 BMS-986189 - Drug Profile 107 BRL-44408 - Drug Profile 108 BTZO-2 - Drug Profile 109 CAR Peptide - Drug Profile 110 ceftaroline fosamil - Drug Profile 111 COG-133 - Drug Profile 114 Cx-611 - Drug Profile 116 CYT-107 - Drug Profile 120 Drug for Sepsis and Septic Shock - Drug Profile 123 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 124 Drugs to Inhibit Sialidase for Sepsis - Drug Profile 125 Escherichia coli vaccine - Drug Profile 126 ethinyl estradiol sulfonate - Drug Profile 127 EV-007156 - Drug Profile 128 Gamma-PN - Drug Profile 129 Glyco-23 - Drug Profile 130 HBN-1 - Drug Profile 131 HBN-3 - Drug Profile 132 HBN-4 - Drug Profile 133 HU-003 - Drug Profile 134 IFX-1 - Drug Profile 135 ImmStem - Drug Profile 137 ImmuneSafe - Drug Profile 138 IMT-504 - Drug Profile 139 IND-006 - Drug Profile 141 IR-999 - Drug Profile 142 Klebsiella pneumoniae vaccine - Drug Profile 143 L-257 - Drug Profile 144 L-97-1 - Drug Profile 145 L-Citrulline - Drug Profile 147 levosimendan - Drug Profile 148 M-33 - Drug Profile 152 M-6229 - Drug Profile 153 meropenem - Drug Profile 154 Metablok - Drug Profile 155 Micselon - Drug Profile 156 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 157 Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 158 Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 159 Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 160 Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 161 Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 162 Motrem - Drug Profile 163 NAV-838 - Drug Profile 164 OPN-305 - Drug Profile 165 OTP-300 - Drug Profile 167 Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile 168 PNV-1 - Drug Profile 169 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 170 RA-101295 - Drug Profile 171 RBM-005 - Drug Profile 172 RECCE-327 - Drug Profile 173 Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile 174 Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 175 Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 178 Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 179 Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 180 Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile 181 Recombinant Protein for Sepsis - Drug Profile 182 Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 183 S-649266 - Drug Profile 184 SAN-101 - Drug Profile 186 Slit2N - Drug Profile 187 Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 188 Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile 189 Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 190 Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 191 Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 192 Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 193 Staphylococcus aureus (multivalent) vaccine - Drug Profile 194 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 195 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 197 Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 202 Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 203 Synthetic Peptides for Infectious Disease - Drug Profile 204 Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 205 Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 206 Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 207 Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile 208 TF-0003 - Drug Profile 209 thrombomodulin alfa - Drug Profile 210 tosatoxumab - Drug Profile 212 TRX-306 - Drug Profile 214 vancomycin hydrochloride - Drug Profile 215 Yersinia pestis vaccine - Drug Profile 216 Sepsis - Dormant Projects 217 Sepsis - Discontinued Products 222 Sepsis - Product Development Milestones 223 Featured News & Press Releases 223 Appendix 232 Methodology 232 Coverage 232 Secondary Research 232 Primary Research 232 Expert Panel Validation 232 Contact Us 232 Disclaimer 233
List of Tables
Number of Products under Development for Sepsis, H2 2016 19 Number of Products under Development for Sepsis - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 22 Number of Products under Development by Companies, H2 2016 (Contd..1) 23 Number of Products under Development by Companies, H2 2016 (Contd..2) 24 Number of Products under Development by Companies, H2 2016 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H2 2016 27 Comparative Analysis by Late Stage Development, H2 2016 28 Comparative Analysis by Clinical Stage Development, H2 2016 29 Comparative Analysis by Early Stage Development, H2 2016 30 Comparative Analysis by Unknown Stage Development, H2 2016 31 Products under Development by Companies, H2 2016 32 Products under Development by Companies, H2 2016 (Contd..1) 33 Products under Development by Companies, H2 2016 (Contd..2) 34 Products under Development by Companies, H2 2016 (Contd..3) 35 Products under Development by Companies, H2 2016 (Contd..4) 36 Products under Investigation by Universities/Institutes, H2 2016 37 Sepsis - Pipeline by Adrenomed AG, H2 2016 38 Sepsis - Pipeline by Altor BioScience Corporation, H2 2016 39 Sepsis - Pipeline by Am-Pharma B.V., H2 2016 40 Sepsis - Pipeline by Arch Biopartners, Inc., H2 2016 41 Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 42 Sepsis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 43 Sepsis - Pipeline by Astellas Pharma Inc., H2 2016 44 Sepsis - Pipeline by Batu Biologics, Inc., H2 2016 45 Sepsis - Pipeline by Biomedica Management Corporation, H2 2016 46 Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 47 Sepsis - Pipeline by Bristol-Myers Squibb Company, H2 2016 48 Sepsis - Pipeline by Cell2B S.A. , H2 2016 49 Sepsis - Pipeline by Chiesi Farmaceutici SpA, H2 2016 50 Sepsis - Pipeline by Chiome Bioscience, Inc., H2 2016 51 Sepsis - Pipeline by Cilian AG, H2 2016 52 Sepsis - Pipeline by Cognosci, Inc., H2 2016 53 Sepsis - Pipeline by Cytheris SA, H2 2016 54 Sepsis - Pipeline by Endacea, Inc., H2 2016 55 Sepsis - Pipeline by Evec, Inc., H2 2016 56 Sepsis - Pipeline by Huons Co., Ltd., H2 2016 57 Sepsis - Pipeline by Immune Response BioPharma, Inc., H2 2016 58 Sepsis - Pipeline by Immunethep, SA, H2 2016 59 Sepsis - Pipeline by ImmunNovative Developments SL, H2 2016 60 Sepsis - Pipeline by InflaRx GmbH, H2 2016 61 Sepsis - Pipeline by Inotrem S.A., H2 2016 62 Sepsis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 63 Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2016 64 Sepsis - Pipeline by Merck & Co., Inc., H2 2016 65 Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 66 Sepsis - Pipeline by OncoImmune, Inc., H2 2016 67 Sepsis - Pipeline by Opsona Therapeutics Limited, H2 2016 68 Sepsis - Pipeline by Orion Oyj, H2 2016 69 Sepsis - Pipeline by ProThera Biologics, LLC., H2 2016 70 Sepsis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 71 Sepsis - Pipeline by Recce Pty Ltd, H2 2016 72 Sepsis - Pipeline by Ribomic Inc., H2 2016 73 Sepsis - Pipeline by Shionogi & Co., Ltd., H2 2016 74 Sepsis - Pipeline by Silence Therapeutics Plc, H2 2016 75 Sepsis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 76 Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 77 Sepsis - Pipeline by Syntiron LLC, H2 2016 78 Sepsis - Pipeline by TaiRx, Inc., H2 2016 79 Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 80 Sepsis - Pipeline by Therakind Limited, H2 2016 81 Sepsis - Pipeline by Therashock, LLC, H2 2016 82 Sepsis - Pipeline by TiGenix NV, H2 2016 83 Sepsis - Pipeline by VBS Pharmaceuticals, H2 2016 84 Sepsis - Pipeline by ViiV Healthcare Limited, H2 2016 85 Sepsis - Pipeline by XImmune AB, H2 2016 86 Assessment by Monotherapy Products, H2 2016 87 Number of Products by Stage and Target, H2 2016 89 Number of Products by Stage and Mechanism of Action, H2 2016 92 Number of Products by Stage and Route of Administration, H2 2016 95 Number of Products by Stage and Molecule Type, H2 2016 97 Sepsis - Dormant Projects, H2 2016 224 Sepsis - Dormant Projects (Contd..1), H2 2016 225 Sepsis - Dormant Projects (Contd..2), H2 2016 226 Sepsis - Dormant Projects (Contd..3), H2 2016 227 Sepsis - Dormant Projects (Contd..4), H2 2016 228 Sepsis - Discontinued Products, H2 2016 229
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
